Literature DB >> 11927840

Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females.

Pailin Ujjin1, Soisungwan Satarug, Yuvaree Vanavanitkun, Satoshi Daigo, Noritaka Ariyoshi, Hiroshi Yamazaki, Paul E B Reilly, Michael R Moore, Tetsuya Kamataki.   

Abstract

The relationships between catalytic activity of cytochrome P450 2A6 (CYP2A6), polymorphism of CYP2A6 gene, gender and levels of body iron stores were analysed in a sample group of 202 apparently healthy Thais, aged 19-47 years. Eleven individuals were found to have high activity of CYP2A6, judged by the relatively large amounts (11.2-14.6 mg) of 7-hydroyxcoumarin (7-OHC) excreted 3 h following administration of 15 mg of coumarin. Ten individuals, however, did not excrete any 7-OHC. Of these 10, four were found to have no CYP2A6 gene (whole gene deletion; CYP2A6*4 allele). The frequency of the CYP2A6 alleles; *1A, *1B and *4 in the whole sample group was 52, 40 and 8% while the frequency of the CYP2A6 gene types; *1A/*1A, *1A/*1B, *1B/*1B, *1A/*4, *1B/*4, *4/*4 was 29, 41, 16, 7, 5 and 2%. Subjects having CYP2A6*1A/*1B gene-type group were found to have higher rates of coumarin 7-hydroxylation compared with those of the CYP2A6*1B/*1B and CYP2A6*1A/*4 gene types. The inter-individual variability in CYP2A6 catalytic activity was therefore attributed in part to the CYP2A6 genetic polymorphism. Variation in CYP2A6 activity in this sample group was not associated with gender but, interestingly, it did show an inverse association with plasma ferritin; an indicator of body iron stores. Higher rates of coumarin 7-hydroxylation were found in individuals with low body iron stores (plasma ferritin < 20 microg/l) compared with subjects having normal body iron store status. Subjects (n = 16) with iron overload (plasma ferritin > 300 microg/l) also tended to have elevated rates of coumarin 7-hydroxylation. These results suggest an increased CYP2A6 expression in subjects who have excessive body iron stores. Further investigations into the underlying factors that may lead to increased expression of CYP2A6 in association with abnormal body iron stores are currently in progress in our laboratory.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927840     DOI: 10.1097/00008571-200204000-00009

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  5 in total

1.  CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking.

Authors:  Wiratchanee Mahavorasirikul; Wichittra Tassaneeyakul; Soisagwan Satarug; Ronnatrai Reungweerayut; Chacrin Na-Bangchang; Kesara Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

2.  Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.

Authors:  M I Veiga; S Asimus; P E Ferreira; J P Martins; I Cavaco; V Ribeiro; T N Hai; M G Petzold; A Björkman; M Ashton; J P Gil
Journal:  Eur J Clin Pharmacol       Date:  2008-11-01       Impact factor: 2.953

3.  The influence of iron stores on cadmium body burden in a Thai population.

Authors:  Roongnapa Apinan; Soisunwan Satarug; Ronnatrai Ruengweerayut; Wiratchanee Mahavorasirikul; Kesara Na-Bangchang
Journal:  Environ Geochem Health       Date:  2009-10-06       Impact factor: 4.609

4.  Evidence for concurrent effects of exposure to environmental cadmium and lead on hepatic CYP2A6 phenotype and renal function biomarkers in nonsmokers.

Authors:  Soisungwan Satarug; Muneko Nishijo; Pailin Ujjin; Yuvaree Vanavanitkun; Jason R Baker; Michael R Moore
Journal:  Environ Health Perspect       Date:  2004-11       Impact factor: 9.031

5.  Combined Risk Assessment of Food-derived Coumarin with in Silico Approaches.

Authors:  Takashi Yamada; Naruo Katsutani; Taeko Maruyama; Tomoko Kawamura; Hiroshi Yamazaki; Norie Murayama; Weida Tong; Yasushi Yamazoe; Akihiko Hirose
Journal:  Food Saf (Tokyo)       Date:  2022-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.